Structural insights into clonal restriction and diversity in T cell recognition of two immunodominant SARS-CoV-2 nucleocapsid epitopes.

Structural insights into clonal restriction and diversity in T cell recognition of two immunodominant SARS-CoV-2 nucleocapsid epitopes.

Publication date: Dec 10, 2025

T cells play a crucial role in clearing SARS-CoV-2 and in forming long-term memory responses to that coronavirus. The highly immunogenic nucleocapsid (N) protein of SARS-CoV-2 is much more conserved than the spike (S) protein across variants of concern, making it an attractive vaccine target for activating cytotoxic CD8 T cells. Of particular interest are the immunodominant N epitopes LLL and SPR. Whereas LLL elicits a clonally restricted T cell response, the response to SPR is highly diverse. To understand the basis for this difference, here we determine structures of T cell receptors (TCRs) bound to LLL-HLA-A2 and SPR-HLA-B7, revealing the structural underpinnings of highly restricted Vα gene usage by LLL-specific TCRs, as well as multiple structural solutions to recognizing SPR and thereby generating a clonally diverse T cell response to that epitope. These structures also provide frameworks for understanding T cell recognition of SARS-CoV-2 variants and other coronaviruses. Finally, we compare the X-ray structures of TCR-LLL-HLA-A2 and TCR-SPR-HLA-B7 complexes with models predicted by multiple versions of AlphaFold, highlighting some success while showing room for improvement. Overall, our findings expand understanding of coronavirus T cell recognition, informing vaccine design and advances in computational modeling approaches.

Open Access PDF

Concepts Keywords
Attractive Coronavirus
Cd8 Cov
Coronaviruses Diverse
Immunogenic Epitopes
Nucleocapsid Hla
Immunodominant
Lll
Nucleocapsid
Restricted
Sars
Spr
Structural
Tcrs
Vaccine
Variants

Semantics

Type Source Name
drug DRUGBANK Spinosad
pathway REACTOME Reproduction
disease MESH included
disease MESH Park
pathway REACTOME Metabolism
disease MESH Severe acute respiratory syndrome
disease MESH COVID 19 pandemic
disease MESH infections
disease MESH CDR3
disease MESH dissociation
drug DRUGBANK Activated charcoal
drug DRUGBANK Water
drug DRUGBANK Tropicamide
drug DRUGBANK L-Tryptophan
drug DRUGBANK L-Tyrosine
drug DRUGBANK L-Phenylalanine
drug DRUGBANK L-Alanine
drug DRUGBANK Indole
drug DRUGBANK L-Leucine
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK L-Arginine
drug DRUGBANK Nitrous oxide
drug DRUGBANK Amino acids
drug DRUGBANK Serine
drug DRUGBANK L-Isoleucine
drug DRUGBANK Tromethamine
drug DRUGBANK Edetic Acid
drug DRUGBANK Urea
drug DRUGBANK Cysteamine
disease MESH MES
drug DRUGBANK Flunarizine
drug DRUGBANK Biotin
drug DRUGBANK Calcium Chloride
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Potassium
drug DRUGBANK Sodium tartrate
drug DRUGBANK Glycerin
disease MESH T1D3
drug DRUGBANK BIA
disease MESH pneumonia
disease MESH Dis
pathway KEGG Viral replication
drug DRUGBANK Coenzyme M
disease MESH vaccinia
disease MESH strains
drug DRUGBANK Nitrogen
drug DRUGBANK Oxygen
drug DRUGBANK Troleandomycin

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *